PMC:7195088 / 57711-58841 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1721","span":{"begin":18,"end":26},"obj":"Species"},{"id":"1722","span":{"begin":513,"end":521},"obj":"Species"},{"id":"1723","span":{"begin":582,"end":590},"obj":"Species"},{"id":"1724","span":{"begin":557,"end":570},"obj":"Chemical"},{"id":"1725","span":{"begin":617,"end":630},"obj":"Chemical"},{"id":"1726","span":{"begin":818,"end":831},"obj":"Chemical"},{"id":"1727","span":{"begin":1083,"end":1096},"obj":"Chemical"},{"id":"1728","span":{"begin":3,"end":17},"obj":"Disease"},{"id":"1729","span":{"begin":76,"end":100},"obj":"Disease"},{"id":"1730","span":{"begin":136,"end":171},"obj":"Disease"},{"id":"1731","span":{"begin":173,"end":177},"obj":"Disease"},{"id":"1732","span":{"begin":246,"end":250},"obj":"Disease"},{"id":"1733","span":{"begin":342,"end":354},"obj":"Disease"},{"id":"1734","span":{"begin":527,"end":531},"obj":"Disease"},{"id":"1735","span":{"begin":943,"end":952},"obj":"Disease"}],"attributes":[{"id":"A1721","pred":"tao:has_database_id","subj":"1721","obj":"Tax:9606"},{"id":"A1722","pred":"tao:has_database_id","subj":"1722","obj":"Tax:9606"},{"id":"A1723","pred":"tao:has_database_id","subj":"1723","obj":"Tax:9606"},{"id":"A1724","pred":"tao:has_database_id","subj":"1724","obj":"MESH:D003907"},{"id":"A1725","pred":"tao:has_database_id","subj":"1725","obj":"MESH:D003907"},{"id":"A1726","pred":"tao:has_database_id","subj":"1726","obj":"MESH:D003907"},{"id":"A1727","pred":"tao:has_database_id","subj":"1727","obj":"MESH:D003907"},{"id":"A1728","pred":"tao:has_database_id","subj":"1728","obj":"MESH:D016638"},{"id":"A1729","pred":"tao:has_database_id","subj":"1729","obj":"MESH:D001778"},{"id":"A1730","pred":"tao:has_database_id","subj":"1730","obj":"MESH:D012128"},{"id":"A1731","pred":"tao:has_database_id","subj":"1731","obj":"MESH:D012128"},{"id":"A1732","pred":"tao:has_database_id","subj":"1732","obj":"MESH:D012128"},{"id":"A1733","pred":"tao:has_database_id","subj":"1733","obj":"MESH:D007249"},{"id":"A1734","pred":"tao:has_database_id","subj":"1734","obj":"MESH:D012128"},{"id":"A1735","pred":"tao:has_database_id","subj":"1735","obj":"MESH:D003643"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"In critically ill patients, corticosteroids may be provided to decrease the inflammation–coagulation–fibroproliferation observed during acute respiratory distress syndrome (ARDS) [[58], [59], [60], [61]]. A meta-analysis on corticosteroid use in ARDS including eight controlled studies reported a significant reduction in markers of systemic inflammation, pulmonary and extrapulmonary organ dysfunction scores, duration of mechanical ventilation and ICU length of stay [62]. A recent multicentre RCT included 277 patients with ARDS to assess the effects of dexamethasone treatment. Patients in the study arm received dexamethasone 20 mg once daily from day 1 to day 5, which was reduced to 10 mg once daily from day 6 to day 10. This study reported a significant reduction in duration of mechanical ventilation in the dexamethasone group than in the control group (between-group difference 4.8 days, p \u003c 0.0001) and a significant reduction in mortality at 60 days (between-group difference −15.3%, p 0.0047). The proportion of adverse events did not differ significantly between the dexamethasone group and the control group [63]."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T91","span":{"begin":385,"end":390},"obj":"Body_part"},{"id":"T92","span":{"begin":604,"end":607},"obj":"Body_part"}],"attributes":[{"id":"A91","pred":"fma_id","subj":"T91","obj":"http://purl.org/sig/ont/fma/fma67498"},{"id":"A92","pred":"fma_id","subj":"T92","obj":"http://purl.org/sig/ont/fma/fma24890"}],"text":"In critically ill patients, corticosteroids may be provided to decrease the inflammation–coagulation–fibroproliferation observed during acute respiratory distress syndrome (ARDS) [[58], [59], [60], [61]]. A meta-analysis on corticosteroid use in ARDS including eight controlled studies reported a significant reduction in markers of systemic inflammation, pulmonary and extrapulmonary organ dysfunction scores, duration of mechanical ventilation and ICU length of stay [62]. A recent multicentre RCT included 277 patients with ARDS to assess the effects of dexamethasone treatment. Patients in the study arm received dexamethasone 20 mg once daily from day 1 to day 5, which was reduced to 10 mg once daily from day 6 to day 10. This study reported a significant reduction in duration of mechanical ventilation in the dexamethasone group than in the control group (between-group difference 4.8 days, p \u003c 0.0001) and a significant reduction in mortality at 60 days (between-group difference −15.3%, p 0.0047). The proportion of adverse events did not differ significantly between the dexamethasone group and the control group [63]."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T46","span":{"begin":385,"end":390},"obj":"Body_part"},{"id":"T47","span":{"begin":604,"end":607},"obj":"Body_part"}],"attributes":[{"id":"A46","pred":"uberon_id","subj":"T46","obj":"http://purl.obolibrary.org/obo/UBERON_0000062"},{"id":"A47","pred":"uberon_id","subj":"T47","obj":"http://purl.obolibrary.org/obo/UBERON_0001460"}],"text":"In critically ill patients, corticosteroids may be provided to decrease the inflammation–coagulation–fibroproliferation observed during acute respiratory distress syndrome (ARDS) [[58], [59], [60], [61]]. A meta-analysis on corticosteroid use in ARDS including eight controlled studies reported a significant reduction in markers of systemic inflammation, pulmonary and extrapulmonary organ dysfunction scores, duration of mechanical ventilation and ICU length of stay [62]. A recent multicentre RCT included 277 patients with ARDS to assess the effects of dexamethasone treatment. Patients in the study arm received dexamethasone 20 mg once daily from day 1 to day 5, which was reduced to 10 mg once daily from day 6 to day 10. This study reported a significant reduction in duration of mechanical ventilation in the dexamethasone group than in the control group (between-group difference 4.8 days, p \u003c 0.0001) and a significant reduction in mortality at 60 days (between-group difference −15.3%, p 0.0047). The proportion of adverse events did not differ significantly between the dexamethasone group and the control group [63]."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T99","span":{"begin":142,"end":162},"obj":"Phenotype"}],"attributes":[{"id":"A99","pred":"hp_id","subj":"T99","obj":"http://purl.obolibrary.org/obo/HP_0002098"}],"text":"In critically ill patients, corticosteroids may be provided to decrease the inflammation–coagulation–fibroproliferation observed during acute respiratory distress syndrome (ARDS) [[58], [59], [60], [61]]. A meta-analysis on corticosteroid use in ARDS including eight controlled studies reported a significant reduction in markers of systemic inflammation, pulmonary and extrapulmonary organ dysfunction scores, duration of mechanical ventilation and ICU length of stay [62]. A recent multicentre RCT included 277 patients with ARDS to assess the effects of dexamethasone treatment. Patients in the study arm received dexamethasone 20 mg once daily from day 1 to day 5, which was reduced to 10 mg once daily from day 6 to day 10. This study reported a significant reduction in duration of mechanical ventilation in the dexamethasone group than in the control group (between-group difference 4.8 days, p \u003c 0.0001) and a significant reduction in mortality at 60 days (between-group difference −15.3%, p 0.0047). The proportion of adverse events did not differ significantly between the dexamethasone group and the control group [63]."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T328","span":{"begin":76,"end":88},"obj":"Disease"},{"id":"T329","span":{"begin":136,"end":171},"obj":"Disease"},{"id":"T330","span":{"begin":142,"end":171},"obj":"Disease"},{"id":"T331","span":{"begin":173,"end":177},"obj":"Disease"},{"id":"T332","span":{"begin":246,"end":250},"obj":"Disease"},{"id":"T333","span":{"begin":342,"end":354},"obj":"Disease"},{"id":"T334","span":{"begin":527,"end":531},"obj":"Disease"}],"attributes":[{"id":"A328","pred":"mondo_id","subj":"T328","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"},{"id":"A329","pred":"mondo_id","subj":"T329","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A330","pred":"mondo_id","subj":"T330","obj":"http://purl.obolibrary.org/obo/MONDO_0009971"},{"id":"A331","pred":"mondo_id","subj":"T331","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A332","pred":"mondo_id","subj":"T332","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A333","pred":"mondo_id","subj":"T333","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"},{"id":"A334","pred":"mondo_id","subj":"T334","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"}],"text":"In critically ill patients, corticosteroids may be provided to decrease the inflammation–coagulation–fibroproliferation observed during acute respiratory distress syndrome (ARDS) [[58], [59], [60], [61]]. A meta-analysis on corticosteroid use in ARDS including eight controlled studies reported a significant reduction in markers of systemic inflammation, pulmonary and extrapulmonary organ dysfunction scores, duration of mechanical ventilation and ICU length of stay [62]. A recent multicentre RCT included 277 patients with ARDS to assess the effects of dexamethasone treatment. Patients in the study arm received dexamethasone 20 mg once daily from day 1 to day 5, which was reduced to 10 mg once daily from day 6 to day 10. This study reported a significant reduction in duration of mechanical ventilation in the dexamethasone group than in the control group (between-group difference 4.8 days, p \u003c 0.0001) and a significant reduction in mortality at 60 days (between-group difference −15.3%, p 0.0047). The proportion of adverse events did not differ significantly between the dexamethasone group and the control group [63]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T318","span":{"begin":205,"end":206},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T319","span":{"begin":295,"end":296},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T320","span":{"begin":385,"end":390},"obj":"http://purl.obolibrary.org/obo/UBERON_0003103"},{"id":"T321","span":{"begin":475,"end":476},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T322","span":{"begin":604,"end":607},"obj":"http://www.ebi.ac.uk/efo/EFO_0001410"},{"id":"T323","span":{"begin":749,"end":750},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T324","span":{"begin":916,"end":917},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"In critically ill patients, corticosteroids may be provided to decrease the inflammation–coagulation–fibroproliferation observed during acute respiratory distress syndrome (ARDS) [[58], [59], [60], [61]]. A meta-analysis on corticosteroid use in ARDS including eight controlled studies reported a significant reduction in markers of systemic inflammation, pulmonary and extrapulmonary organ dysfunction scores, duration of mechanical ventilation and ICU length of stay [62]. A recent multicentre RCT included 277 patients with ARDS to assess the effects of dexamethasone treatment. Patients in the study arm received dexamethasone 20 mg once daily from day 1 to day 5, which was reduced to 10 mg once daily from day 6 to day 10. This study reported a significant reduction in duration of mechanical ventilation in the dexamethasone group than in the control group (between-group difference 4.8 days, p \u003c 0.0001) and a significant reduction in mortality at 60 days (between-group difference −15.3%, p 0.0047). The proportion of adverse events did not differ significantly between the dexamethasone group and the control group [63]."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T98872","span":{"begin":28,"end":43},"obj":"Chemical"},{"id":"T54230","span":{"begin":224,"end":238},"obj":"Chemical"},{"id":"T17441","span":{"begin":557,"end":570},"obj":"Chemical"},{"id":"T90766","span":{"begin":617,"end":630},"obj":"Chemical"},{"id":"T70095","span":{"begin":818,"end":831},"obj":"Chemical"},{"id":"T42283","span":{"begin":832,"end":837},"obj":"Chemical"},{"id":"T49874","span":{"begin":858,"end":863},"obj":"Chemical"},{"id":"T47088","span":{"begin":873,"end":878},"obj":"Chemical"},{"id":"T59830","span":{"begin":973,"end":978},"obj":"Chemical"},{"id":"T57744","span":{"begin":1083,"end":1096},"obj":"Chemical"},{"id":"T54060","span":{"begin":1097,"end":1102},"obj":"Chemical"},{"id":"T69982","span":{"begin":1119,"end":1124},"obj":"Chemical"}],"attributes":[{"id":"A47349","pred":"chebi_id","subj":"T98872","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"},{"id":"A47612","pred":"chebi_id","subj":"T54230","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"},{"id":"A86091","pred":"chebi_id","subj":"T17441","obj":"http://purl.obolibrary.org/obo/CHEBI_41879"},{"id":"A38942","pred":"chebi_id","subj":"T90766","obj":"http://purl.obolibrary.org/obo/CHEBI_41879"},{"id":"A87609","pred":"chebi_id","subj":"T70095","obj":"http://purl.obolibrary.org/obo/CHEBI_41879"},{"id":"A90364","pred":"chebi_id","subj":"T42283","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A30689","pred":"chebi_id","subj":"T49874","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A93496","pred":"chebi_id","subj":"T47088","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A26592","pred":"chebi_id","subj":"T59830","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A83478","pred":"chebi_id","subj":"T57744","obj":"http://purl.obolibrary.org/obo/CHEBI_41879"},{"id":"A50932","pred":"chebi_id","subj":"T54060","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A33625","pred":"chebi_id","subj":"T69982","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"}],"text":"In critically ill patients, corticosteroids may be provided to decrease the inflammation–coagulation–fibroproliferation observed during acute respiratory distress syndrome (ARDS) [[58], [59], [60], [61]]. A meta-analysis on corticosteroid use in ARDS including eight controlled studies reported a significant reduction in markers of systemic inflammation, pulmonary and extrapulmonary organ dysfunction scores, duration of mechanical ventilation and ICU length of stay [62]. A recent multicentre RCT included 277 patients with ARDS to assess the effects of dexamethasone treatment. Patients in the study arm received dexamethasone 20 mg once daily from day 1 to day 5, which was reduced to 10 mg once daily from day 6 to day 10. This study reported a significant reduction in duration of mechanical ventilation in the dexamethasone group than in the control group (between-group difference 4.8 days, p \u003c 0.0001) and a significant reduction in mortality at 60 days (between-group difference −15.3%, p 0.0047). The proportion of adverse events did not differ significantly between the dexamethasone group and the control group [63]."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T25","span":{"begin":76,"end":88},"obj":"http://purl.obolibrary.org/obo/GO_0006954"},{"id":"T26","span":{"begin":89,"end":100},"obj":"http://purl.obolibrary.org/obo/GO_0050817"},{"id":"T27","span":{"begin":342,"end":354},"obj":"http://purl.obolibrary.org/obo/GO_0006954"}],"text":"In critically ill patients, corticosteroids may be provided to decrease the inflammation–coagulation–fibroproliferation observed during acute respiratory distress syndrome (ARDS) [[58], [59], [60], [61]]. A meta-analysis on corticosteroid use in ARDS including eight controlled studies reported a significant reduction in markers of systemic inflammation, pulmonary and extrapulmonary organ dysfunction scores, duration of mechanical ventilation and ICU length of stay [62]. A recent multicentre RCT included 277 patients with ARDS to assess the effects of dexamethasone treatment. Patients in the study arm received dexamethasone 20 mg once daily from day 1 to day 5, which was reduced to 10 mg once daily from day 6 to day 10. This study reported a significant reduction in duration of mechanical ventilation in the dexamethasone group than in the control group (between-group difference 4.8 days, p \u003c 0.0001) and a significant reduction in mortality at 60 days (between-group difference −15.3%, p 0.0047). The proportion of adverse events did not differ significantly between the dexamethasone group and the control group [63]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T425","span":{"begin":0,"end":204},"obj":"Sentence"},{"id":"T426","span":{"begin":205,"end":474},"obj":"Sentence"},{"id":"T427","span":{"begin":475,"end":581},"obj":"Sentence"},{"id":"T428","span":{"begin":582,"end":728},"obj":"Sentence"},{"id":"T429","span":{"begin":729,"end":1008},"obj":"Sentence"},{"id":"T430","span":{"begin":1009,"end":1130},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In critically ill patients, corticosteroids may be provided to decrease the inflammation–coagulation–fibroproliferation observed during acute respiratory distress syndrome (ARDS) [[58], [59], [60], [61]]. A meta-analysis on corticosteroid use in ARDS including eight controlled studies reported a significant reduction in markers of systemic inflammation, pulmonary and extrapulmonary organ dysfunction scores, duration of mechanical ventilation and ICU length of stay [62]. A recent multicentre RCT included 277 patients with ARDS to assess the effects of dexamethasone treatment. Patients in the study arm received dexamethasone 20 mg once daily from day 1 to day 5, which was reduced to 10 mg once daily from day 6 to day 10. This study reported a significant reduction in duration of mechanical ventilation in the dexamethasone group than in the control group (between-group difference 4.8 days, p \u003c 0.0001) and a significant reduction in mortality at 60 days (between-group difference −15.3%, p 0.0047). The proportion of adverse events did not differ significantly between the dexamethasone group and the control group [63]."}

{"project":"2_test","denotations":[{"id":"32360444-22088618-22369798","span":{"begin":181,"end":183},"obj":"22088618"},{"id":"32360444-7587435-22369799","span":{"begin":187,"end":189},"obj":"7587435"},{"id":"32360444-11934726-22369800","span":{"begin":193,"end":195},"obj":"11934726"},{"id":"32360444-21983371-22369801","span":{"begin":199,"end":201},"obj":"21983371"},{"id":"32360444-19325471-22369802","span":{"begin":470,"end":472},"obj":"19325471"},{"id":"32360444-32043986-22369803","span":{"begin":1126,"end":1128},"obj":"32043986"}],"text":"In critically ill patients, corticosteroids may be provided to decrease the inflammation–coagulation–fibroproliferation observed during acute respiratory distress syndrome (ARDS) [[58], [59], [60], [61]]. A meta-analysis on corticosteroid use in ARDS including eight controlled studies reported a significant reduction in markers of systemic inflammation, pulmonary and extrapulmonary organ dysfunction scores, duration of mechanical ventilation and ICU length of stay [62]. A recent multicentre RCT included 277 patients with ARDS to assess the effects of dexamethasone treatment. Patients in the study arm received dexamethasone 20 mg once daily from day 1 to day 5, which was reduced to 10 mg once daily from day 6 to day 10. This study reported a significant reduction in duration of mechanical ventilation in the dexamethasone group than in the control group (between-group difference 4.8 days, p \u003c 0.0001) and a significant reduction in mortality at 60 days (between-group difference −15.3%, p 0.0047). The proportion of adverse events did not differ significantly between the dexamethasone group and the control group [63]."}